Picture of Lixte Biotechnology Holdings logo

LIXT Lixte Biotechnology Holdings Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Annual cashflow statement for Lixte Biotechnology Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-6.73-6.31-5.09-3.59-6.01
Non-Cash Items2.61.550.7730.4182.53
Unusual Items
Other Non-Cash Items
Changes in Working Capital-0.0130.1550.0210.0030.413
Change in Prepaid Expenses
Change in Other Assets
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-4.14-4.61-4.29-3.16-3.07
Other Investing Cash Flow Items-3.17
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-3.17
Financing Cash Flow Items-0.010
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Cash from Financing Activities3.95.143.14010.3
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-0.2460.53-1.15-3.164.07